Advertisement
Singapore markets close in 33 minutes

  • Straits Times Index

    3,176.85
    -10.81 (-0.34%)
     

  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • FTSE 100

    7,827.25
    -49.80 (-0.63%)
     

  • Bitcoin USD

    64,931.44
    +3,937.02 (+6.45%)
     

  • CMC Crypto 200

    1,338.48
    +25.85 (+1.97%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • Dow

    37,775.38
    +22.07 (+0.06%)
     

  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     

  • Gold

    2,398.00
    0.00 (0.00%)
     

  • Crude Oil

    83.03
    +0.30 (+0.36%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • FTSE Bursa Malaysia

    1,550.74
    +5.98 (+0.39%)
     

  • Jakarta Composite Index

    7,092.72
    -74.10 (-1.03%)
     

  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

EU clears Mylan's purchase of Pfizer's Upjohn unit with conditions

Reuters
·1-min read

BRUSSELS (Reuters) - The European Commission said on Wednesday it had approved generic drugmaker Mylan NV's <MYL.O> planned purchase of Pfizer's <PFE.N> off-patient branded drugs business Upjohn, subject to conditions.

The Commission, which oversees competition policy in the European Union, said its investigation had focused on genericised medicines, which are sold to pharmacies and hospitals, with overlaps in a number of fields.

Mylan and Upjohn have offered to divest Mylan's certain generic medicines across 20 countries in the European Economic Area and the United Kingdom, the Commission said.

Pfizer announced the deal in July as part of a strategy allowing it to focus on its more profitable newer medicines.

(Reporting by Philip Blenkinsop)